1 / 4

Novel Insights of Primary Sclerosing Cholangitis Treatment Market

The primary sclerosing cholangitis treatment market is predicted to increase rapidly with improved primary sclerosing cholangitis diagnosis and safe and effective treatment options. Furthermore, the increasing prevalence of primary sclerosing cholangitis, as well as an increase in inflammatory bowel disease, ulcerative colitis, and Crohn's disease, is moving the primary sclerosing cholangitis treatment market ahead.

xmichael
Télécharger la présentation

Novel Insights of Primary Sclerosing Cholangitis Treatment Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Novel Insights of Primary Sclerosing Cholangitis Treatment Market Primary Sclerosing Cholangitis - Treatment and Unmet Needs The primary sclerosing cholangitis treatment market has several major unmet needs, including a lack of effective therapies, proven surveillance strategies, tools for early detection of malignancies, impact on quality of life (QoL), and surrogate endpoints in primary sclerosing cholangitis clinical trials. Furthermore, the American College of Gastroenterology reports that 70% of primary sclerosing cholangitis patients are men, with an average age of 40 at the time of diagnosis. Up to 90% of patients with primary sclerosing cholangitis have inflammatory bowel illness. Ulcerative colitis, the more frequent of the two forms of inflammatory bowel disease, affects roughly 87% of individuals with primary sclerosing cholangitis, while Crohn's disease affects the other 13%. On the other hand, primary sclerosing cholangitis affects just 4% of all people with inflammatory bowel disease.

  2. Current primary sclerosing cholangitis treatment landscape: Complicated Unfortunately, there are no disease-specific authorized medications for the treatment of primary sclerosing cholangitis. Because there is a trend toward better survival, high-dose ursodeoxycholic acid is utilized to treat patients with primary sclerosing cholangitis. Endoscopic treatment should be used for dominant bile duct stenosis. However, liver transplantation remains the sole primary sclerosing cholangitis therapeutic option for those with advanced disease. Furthermore, ursodeoxycholic acid treatment for primary sclerosing cholangitis improves abnormal biochemical testing. It appears to function by improving bile flow and avoiding liver cell damage, but it has little effect on survival or the need for liver transplantation. Furthermore, research has indicated that large doses may be dangerous. Cilofexor: A potential first-approved primary sclerosing cholangitis drug Gilead Sciences, Phenex Pharmaceuticals, HighTide Therapeutics, Dr. Falk Pharma, Mirum Pharmaceuticals, Pliant Therapeutics, Inc, NGM Biopharmaceuticals, CymaBay Therapeutics, and Chemomab Therapeutics are among the key market players in the primary sclerosing cholangitis treatment industry. There is a list of late-stage assets with distinct MoA that are being developed for the treatment of primary sclerosing cholangitis patients and are expected to enter the primary sclerosing cholangitis treatment market of the United States, EU5 (Germany, Italy, France, Spain, and the United Kingdom), Nordic countries (Sweden, Finland, Denmark, and Norway), and Japan in the coming years. Cilotexor (Gilead Sciences/Phenex Pharmaceuticals), Volixibat (Mirum Pharmaceuticals, Inc.), norursodeoxycholic acid (Dr. Falk Pharma; EA Pharma), and HTD1801 (HighTide Biopharma) are a few of the compounds in the primary sclerosing cholangitis pipeline. Cilofexor (Gilead Sciences/Phenex Pharmaceuticals) is a nonsteroidal FXR agonist that is powerful, selective, and orally active. It is an experimental drug for the treatment of PSC, a chronic cholestatic liver disease with few therapeutic choices for patients and considerable unmet requirements. Cilotexor is now being evaluated in the phase III PRIMIS research, which is being conducted in several sites worldwide to determine the safety, tolerability, and efficacy of cilofexor in non-cirrhotic individuals with primary sclerosing cholangitis. It is predicted to enter the primary sclerosing cholangitis therapy market in the United States by 2025. The primary sclerosing cholangitis treatment market is all set to grow significantly As there is no approved therapy, the first drug approved in the primary sclerosing cholangitis market will have a competitive advantage. Several major pharmaceutical companies are actively

  3. developing novel medications for the treatment of primary sclerosing cholangitis. As a result, the development of disease-specific primary sclerosing cholangitis therapies bodes well for the primary sclerosing cholangitis treatment market landscape, allowing for major changes during the projection period (2019–2032). The primary sclerosing cholangitis treatment market is predicted to increase rapidly with improved primary sclerosing cholangitis diagnosis and safe and effective treatment options. Furthermore, the increasing prevalence of primary sclerosing cholangitis, as well as an increase in inflammatory bowel disease, ulcerative colitis, and Crohn's disease, is moving the primary sclerosing cholangitis treatment market ahead. Nonetheless, pricing and reimbursement issues, as well as associated long-term side effects of approved medications, are two important variables influencing the success of emerging therapeutics in the primary sclerosing cholangitis therapy market. Related Reports: Diagnostic Imaging Equipment Market Diagnostic Imaging Equipment Market By Product (X-Ray Imaging Systems, Computed Tomography (CT) Scanners, Ultrasound Systems, Magnetic Resonance Imaging (MRI) Systems, Nuclear Imaging Systems, Mammography Systems, And Others), By Application (Cardiology, Oncology, Gastroenterology, Gynecology, And Other Applications), By End-User (Hospitals, Diagnostic Imaging Centres, And Others), by geography is expected to grow at a steady CAGR forecast till 2026 owing to rising technological advancement and increasing prevalence of chronic diseases. Invasive Candidiasis Market "DelveInsight’s ‘Invasive Candidiasis Market Insight, Competitive Landscape and Market Forecast, 2027’ report delivers an in-depth understanding of Invasive Candidiasis and the historical and forecasted Invasive Candidiasis market trends, globally, which comprises of North America, Europe, APAC, and RoW. Sialidosis Market DelveInsight's "Sialidosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Sialidosis, historical and forecasted epidemiology as well as the Sialidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Filgrastim Biosimilar Insight DelveInsight’s, “Filgrastim Biosimilar Insight, 2022,” report provides comprehensive insights about 20+ companies and 20+ marketed and pipeline drugs in the Filgrastim Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products. It also covers the

  4. therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Ventricular Assist Devices (VAD) Market Ventricular Assist Devices (VAD) Market By Type Of Devices (Neuromodulation & Neurostimulation Devices, Analgesic Infusion Pumps [Intrathecal Infusion Pumps and External Infusion Pumps], Ablation Devices [Radiofrequency Ablation Devices And Cryoablation Devices], And Others), By Application (Neuropathic Pain, Cancer Pain, Facial & Migraine Pain, Musculoskeletal Pain, and Others), By Geography is expected to grow at a steady CAGR Forecast till 2027 Latest Reports by DelveInsight Basal Cell Carcinoma Market | Birch Allergy Market | Bile Duct Neoplasm Market | Gingivitis Market | Lupus Nephritis Market | Severe Hypertriglyceridemia (SHTG) Market | Arthralgia Market | Severe Hypertriglyceridemia (SHTG) Market | Arthralgia Market | Congestive Heart Failure Market | Gingivitis Market | Lupus Nephritis Market | Erythromelalgia Market | AL Amyloidosis Market | Primordial Dwarfism Market | Breast Pumps Market | Hyperuricemia Market | Helicobacter Pylori (H. pylori) Infection Market | AIDS Dementia- Market | Follicular Lymphoma Market | Chronic Pulmonary Hypertension Market | Adrenal Crisis Market | Retinoblastoma Market | Non-Cystic Fibrosis Bronchiectasis Market | Microsatellite Stable Colorectal Cancer Market | Chondrosarcoma Market | Sialidosis Market To know more about our Competitive Services, Click here: Pharma Competitive Intelligence https://www.delveinsight.com/consulting/competitive-intelligence-services Also, take a glance at the Blogs by DelveInsight: ● ● ● ● How Metaverse is Set to Transform the Healthcare Dynamics? Role of Mobile Technology in Hemophilia Management How 3D Bioprinting Technology is Revolutionizing the Healthcare Industry? How Cloud Computing is Transforming the Healthcare Industry Dynamics?

More Related